<DOC>
	<DOC>NCT02685189</DOC>
	<brief_summary>The purpose of this protocol is to provide a mechanism to collect Long Term Clinical Data from those babies who participated in the primary Study 64,185-06-2(W)(WS)(ISNHP) "An Open-Label Study Of The Safety And Clinical Pharmacology Of Stanate® In Infants At-Risk For Exchange Transfusion".</brief_summary>
	<brief_title>Long-Term Clinical Follow-Up of Children Enrolled in Stannsoporfin Clinical Trial Protocol No. 64,185-06-2(W)</brief_title>
	<detailed_description>The purpose of this protocol is to provide a mechanism to collect Clinical Data from those babies who participated in the primary Study 64,185-06-2(W)(WS)(ISNHP) "An Open-Label Study Of The Safety And Clinical Pharmacology Of Stanate® In Infants At-Risk For Exchange Transfusion". Data on long-term impact of Stannsoporfin on the physical, neurological, neurodevelopmental, biochemical, metabolic and hematopoietic profiles of the children will be collected at 9 and 18 months, 3, 6 and 9 years after Stannsoporfin administration</detailed_description>
	<mesh_term>Hyperbilirubinemia</mesh_term>
	<mesh_term>Tin mesoporphyrin</mesh_term>
	<criteria>All children who have been enrolled and received Stanate® Injection/Placebo in Study Protocol 64,185062(W)(WS)(ISNHP) are eligible for this followup.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Days</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>